Naslov
First-­line­ H. pylori eradication therapy in Europe: Results from 24,882 cases of the European Registry on H. pylori Management­(Hp-­EuReg)

Autori
O. P. Nyssen ; D. Bordin ; B. Tepes ; A. Pérez-Aisa ; D. Vaira ; M. Caldas ; L. Bujanda ; M. Castro- Fernandez ; F. Frode Lerang ; M. Leja ; L. Rodrigo ; T. Rokkas ; L. Kupcinskas ; J. Pérez-Lasala ; L. Jonaitis ; O. Shvets ; A. Gasbarrini ; H. Simsek ; A. T. R Axon ; G. M. Buzás ; J. Machado ; Y. Niv ; L. Boyanova ; A. Goldis ; V. Lamy ; Ante Tonkić ; K. Przytulski ; C. Beglinger ; M. Venerito ; P. Bytzer ; L. G. Capelle ; T. Milosavljevic ; V. Milivojevic ; L. Veijola ; J. Molina-Infante ; L. Vologzhanina ; G. Fadeenko ; I. Ariño ; G. Fiorini ; A. Garre ; J. Garrido ; C. F. Pérez ; F. Heluwaert ; I. Puig ; F. Mégraud ; C. O'Morain ; J. P. Gisbert

Kolaboracija
Hp-EuReg Investigators

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
The Year in Helicobacter. XXXIIIrd International Workshop on Helicobacter & Microbiota in Inflammation & Cancer / - , 2020, 12-13

Skup
International Workshop on Helicobacter and Microbiota in Inflammation and Cancer

Mjesto i datum
Online, 12.09.2020. - 12.09.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Helicobacter pylori ; eradication therapy

Sažetak
Background: The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design: International multicentre prospective non- interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap up to April 2020. Variables included: demographics, previous eradication at-tempts, prescribed treatment, adverse events, and outcomes. Modified intention-to-treat (mITT) and per- protocol (PP) analyses were performed and data were subject to quality review to ensure information reliability. Results: In total 36, 319 patients from 29 European countries were evaluated and 24, 882 (70%) first-line empirical H. pylori treatments were included for analysis. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (40%), followed by concomitant treatment (19%) and bismuth quadruple (Pylera®) (10%) achieving 83%, 91% and 95% mITT eradication rate, respectively. Over 90% effectiveness was obtained only with 10 and 14-day bismuth quadruple or 14-day concomitant treatment. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Conclusions: Management of H. pylori infection by European gastroenterologists is heterogeneous. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA